High-Glucose-Induced Endothelial Cell Injury Is Inhibited by a Peptide Derived from Human Apolipoprotein E

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Bhattacharjee, Partha S ^a,b   Huq, Tashfin S ^c   Potter, Valencia ^d   Young, Anna ^e   Davenport, Ian R ^a   Graves, Richard ^a   Mandal, Tarun K ^a   Clement, Christian ^b   McFerrin, Harris E ^a   Muniruzzaman, Syed ^a   Ireland, Shubha K ^a   Hill, James M ^b,f  

^a XAVIER UNIVERSITY OF LOUISIANA   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

^e ALLEGHENY COLLEGE   (United States)

^f LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E MIMETIC PEPTIDE; GLUCOSE; HEPARAN SULFATE; HEPARANASE; OCCLUDIN; STREPTOZOCIN; UNCLASSIFIED DRUG; ZONA OCCLUDIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD RETINA BARRIER; CELL DAMAGE; DIABETES MELLITUS; ENDOTHELIUM CELL; ENZYME DEGRADATION; ENZYME INHIBITION; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; HUMAN RETINAL ENDOTHELIAL CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TIGHT JUNCTION; WESTERN BLOTTING;

ANIMALS; APOLIPOPROTEINS E; ENDOTHELIAL CELLS; EXTRACELLULAR MATRIX; GLUCOSE; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-1; MICE; PEPTIDES; RETINA; TIGHT JUNCTION PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84871293609     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052152     Document Type: Article

References (31)

1. Ruderman NB, Williamson JR, Brownlee M, (1992) Glucose and diabetic vascular disease. FASEB J 6: 2905-2914.
2. Lee TS, Saltsman KA, Ohashi H, King GL, (1989) Activation of protein kinase C by elevation of glucose concentration: proposal for a mechanism in the development of diabetic vascular complications. Proc Natl Acad Sci U S A 86: 5141-5145.
3. Kamata K, Miyata N, Abiru T, Kasuya Y, (1992) Functional changes in vascular smooth muscle and endothelium of arteries during diabetes mellitus. Life Sci 50: 1379-1387.
4. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, et al. (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331: 1480-1487.
5. Muir H, (1977) Structure and function of proteoglycans of cartilage and cell-matrix interactions. Soc Gen Physiol Ser 32: 87-99.
6. Hook M, Kjellen L, Johansson S, (1984) Cell-surface glycosaminoglycans. Ann Rev Biochem 53: 847-869.
7. Kraemer PM, (1971) Heparan sulfates of cultured cells. I. Membrane-associated and cell-sap species in Chinese hamster cells. Biochemistry 10: 1437-1445.
8. Hedman K, Johansson S, Vartio T, Kjellen L, Vaheri A, et al. (1982) Structure of the pericellular matrix: association of heparan and chondroitin sulfates with fibronectin-procollagen fibers. Cell 28: 663-671.
9. Hardebo JE, Kahrstrom J, (1985) Endothelial negative surface charge areas and blood-brain barrier function. Acta Physiol Scand 125: 495-499.
10. Van Den Born J, Van Den Heuvel LP, Bakker MA, Veerkamp JH, Assmann KJ, et al. (1992) A monoclonal antibody against GBM heparan sulfate induces an acute selective proteinuria in rats. Kidney Int 41: 115-123.
11. Van Den Born J, Van Den Heuvel LP, Bakker MA, Veerkamp JH, Assmann KJ, et al. (1993) Distribution of GBM heparan sulfate proteoglycan core protein and side chains in human glomerular diseases. Kidney Int 43: 454-463.
12. Katz A, Van-Dijk DJ, Aingorn H, Erman A, Davies M, et al. (2002) Involvement of human heparanase in the pathogenesis of diabetic nephropathy. Isr Med Assoc J 4: 996-1002.
13. Harhaj NS, Antonetti DA, (2004) Regulation of tight junctions and loss of barrier function in pathophysiology. International J Biochem Cell Biol 36: 1206-1237.
14. Barber AJ, Antonetti DA, (2003) Mapping the blood vessels with paracellular permeability in the retinas of diabetic rats. Invest Ophthalmol Vis Sci 44: 5410-5416.
15. Roider J, Brinkmann R, Wirbelauer C, Laqua H, Birngruber R, (2000) Subthreshold (retinal pigment epithelium) photocoagulation in macular diseases: a pilot study. Br J Ophthalmol 84: 40-47.
16. Shafat I, Ilan N, Zoabi S, Vlodavsky I, Nakhoul F, (2011) Heparanase levels are elevated in the urine and plasma of type 2 diabetes patients and associate with blood glucose levels. PLoS ONE 6: e17312.
17. Vreys V, Delande N, Zhang Z, Coomans C, Roebroek A, et al. (2005) Cellular uptake of mammalian heparanase precursor involves low density lipoprotein receptor-related proteins, mannose 6-phosphate receptors, and heparan sulfate proteoglycans. J Biol Chem 280: 33141-33148.
18. Zhu Y, Hui DY, (2003) Apolipoprotein E binding to low density lipoprotein receptor-related protein-1 inhibits cell migration via activation of cAMP-dependent protein kinase A. J Biol Chem 278: 36257-36263.
19. Laskowitz DT, McKenna SE, Song P, Wang H, Durham L, et al. (2007) COG1410, a novel apolipoprotein E-based peptide, improves functional recovery in a murine model of traumatic brain injury. J Neurotrauma 24: 1093-1107.
20. Bhattacharjee PS, Neumann DM, Foster TP, Clement C, Singh G, et al. (2008) Effective treatment of ocular HSK with a human apolipoprotein E mimetic peptide in a mouse eye model. Invest Ophthalmol Vis Sci 49: 4263-4268.
21. Bhattacharjee PS, Neumann DM, Hill JM, (2009) A human apolipoprotein E mimetic peptide effectively inhibits HSV-1 TK-positive and TK-negative acute epithelial keratitis in rabbits. Curr Eye Res 34: 99-102.
22. Dobson CB, Sales SD, Hoggard P, Wozniak MA, Crutcher KA, (2006) The receptor-binding region of human apolipoprotein E has direct anti-infective activity. J Infect Dis 193: 442-450.
23. Bhattacharjee PS, Huq TS, Mandal TK, Graves RA, Muniruzzaman S, et al. (2011) A novel peptide derived from human apolipoprotein E is an inhibitor of tumor growth and ocular angiogenesis. PLoS ONE 6: e15905.
24. Miyamoto K, Khosrof S, Bursell SE, Moromizato Y, Aiello LP, et al. (2000) Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). Am J Pathol 156: 1733-1739.
25. Joussen AM, Smyth N, Niessen C, (2007) Pathophysiology of diabetic macular edema. Dev Ophthalmol 39: 1-12.
26. Moss SE, Klein R, Klein BE, (1998) The 14-year incidence of visual loss in a diabetic population. Ophthalmology 105: 998-1003.
27. Gil N, Goldberg R, Neuman T, Garsen M, Zcharia E, et al. (2012) Heparanase is essential for the development of diabetic nephropathy in mice. Diabetes 61: 208-216.
28. Poon GM, Gariepy J, (2007) Cell-surface proteoglycans as molecular portals for cationic peptide and polymer entry into cells. Biochem Soc Trans 35: 788-793.
29. Richard JP, Melikov K, Vives E, Ramos C, Verbeure B, et al. (2003) Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J Biol Chem 278: 585-590.
30. Amand HL, Rydberg HA, Fornander LH, Lincoln P, Nordén B, et al. (2012) Cell surface binding and uptake of arginine- and lysine-rich penetratin peptides in absence and presence of proteoglycans. Biochim Biophys Acta June 15 [Epub ahead of print].
31. Haas AK, Maisel D, Adelmann J, von Schwerin C, Kahnt I, et al. (2012) Human-protein-derived peptides for intracellular delivery of biomolecules. Biochem J 442: 583-593.